[Research Progress of Immunotherapy for Non-small Cell Lung Cancer 
with Drive Gene Mutation].

Autor: Deng R; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.; Department of 
Oncology, Zhuzhou Second Hospital, Zhuzhou 412000, China., Zeng Y; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China., Pan Y; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China., Hu C; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.; Hunan Cancer Mega-data Intelligent Application and Engineering 
Research Centre, Changsha 410011, China., Wu F; Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, China.; Hunan Cancer Mega-data Intelligent Application and Engineering 
Research Centre, Changsha 410011, China.; Hunan Key Laboratory of Tumor Models and Individualized Medicine, Changsha 410011, China.; Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, Changsha 410011, China.
Jazyk: čínština
Zdroj: Zhongguo fei ai za zhi = Chinese journal of lung cancer [Zhongguo Fei Ai Za Zhi] 2022 Mar 20; Vol. 25 (3), pp. 201-206.
DOI: 10.3779/j.issn.1009-3419.2022.102.06
Abstrakt: Lung cancer is the most lethal malignancy around the world and non-small cell lung cancer (NSCLC) accounts for 80% of all cases. Most of the NSCLC patients has "driver gene mutations" and targeted therapy achieved a relatively good efficacy, but some patients progressed or relapsed after treatment. Previous studies demonstrated that immune checkpoint inhibitor could improve the prognosis of advanced-stage NSCLC and prolong the survival time. However, the efficacy of immune therapy varies in NSCLC patients with different immune and molecular features. The efficacy of immune therapy was controversial in NSCLC patients with driver gene mutation. The present review will summarize the immune characteristics of NSCLC patients with driver mutation and the directions of immunotherapy for patients with driver mutation.
.
Databáze: MEDLINE
Externí odkaz: